A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections

Abstract BackgroundReal-world data assessing outcomes of immunocompromised patients treated with ceftolozane/tazobactam (C/T) are limited. This study evaluated treatment and clinical outcomes of immunocompromised patients receiving C/T for multidrug-resistant (MDR) Pseudomonas aeruginosa. MethodsThi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Open Forum Infectious Diseases 2021-03, Vol.8 (3), p.ofab089-ofab089
Hauptverfasser:	Hart, Delaney E, Gallagher, Jason C, Puzniak, Laura A, Hirsch, Elizabeth B
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Bacterial pneumonia Care and treatment Comorbidity Disease susceptibility Drug resistance in microorganisms Immunocompromised host Immunosuppressive agents Immunotherapy International economic relations Major Medical research Medicine, Experimental Metronidazole Mortality Patient outcomes Pharmaceutical industry Pneumonia Pseudomonas aeruginosa Risk factors Transplantation of organs, tissues, etc United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!